{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:45:37Z","timestamp":1792521937403,"version":"4.5.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The aim of this review is to examine and evaluate published literature associated with idiopathic inflammatory myopathies (IIM) and interstitial lung disease (ILD) based on myositis specific autoantibodies (MSA) and the potential clinical significance of each autoantibody subtype for the practicing clinician. The review is a comprehensive search of literature published in PubMed from the year 2005 and onward coinciding with the surge in the discovery of new MSAs. Additionally, we comment on recommended multidisciplinary longitudinal care practices for patients with IIM-ILD with regard to imaging and other testing. Treatment is not covered in this review.<\/jats:p>","DOI":"10.3389\/fmed.2023.1117071","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:22:10Z","timestamp":1686644530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Myositis interstitial lung disease and autoantibodies"],"prefix":"10.3389","volume":"10","author":[{"given":"Shire","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","article-title":"Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan","volume":"45","author":"Furst","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study","volume":"56","author":"Svensson","year":"2017","journal-title":"Rheumatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3346\/jkms.2019.34.e55","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a Nationwide population-based study","volume":"34","author":"Cho","year":"2019","journal-title":"J Korean Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"751181","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in global prevalence of interstitial lung disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1378\/chest.65.4.403","article-title":"Interstitial pneumonitis in association with Polymyositis and Dermatomyositis","volume":"65","author":"Frazier","year":"1974","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jalm\/jfab108","article-title":"Myositis antibodies and interstitial lung disease","volume":"7","author":"Basuita","year":"2022","journal-title":"J Appl Lab Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ana.26412","article-title":"Epidemiology survival, and clinical characteristics of inclusion body myositis","volume":"92","author":"Lindgren","year":"2022","journal-title":"Ann Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/ard.2008.093161","article-title":"Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences","volume":"68","author":"Bernatsky","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"ref13","volume-title":"Interstitial lung disease","author":"Antoine","year":"2022"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur Respir Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin Chest Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Mex)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14728214.2020.1787985","article-title":"Clinical trials and novel therapeutics in dermatomyositis","volume":"25","author":"Chandra","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/rir-2022-0001","article-title":"Myositis-specific antibodies: overview and clinical utilization","volume":"3","author":"Halilu","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archneur.60.5.780","article-title":"History of Dermatomyositis","volume":"60","author":"Levine","year":"2003","journal-title":"Arch Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11926-018-0726-4","article-title":"New myositis classification criteria\u2014what we have learned since Bohan and Peter","volume":"20","author":"Leclair","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and Dermatomyositis","volume":"292","author":"Bohan","year":"","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and Dermatomyositis","volume":"292","author":"Bohan","year":"","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20431\/2456-057X.0201001","article-title":"Polymyositis mimicking inflammatory dystrophy","volume":"2","author":"Ramanathan","year":"2017","journal-title":"ARC J Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0226084","DOI":"10.1371\/journal.pone.0226084","article-title":"Meta-analysis of the radiological and clinical features of usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP)","volume":"15","author":"Ebner","year":"2020","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0240347","DOI":"10.1371\/journal.pone.0240347","article-title":"Organizing pneumonia of COVID-19: time-dependent evolution and outcome in CT findings","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.4103\/0973-3698.332977","article-title":"Interstitial pneumonia with autoimmune features","volume":"16","author":"Karjigi","year":"2021","journal-title":"Indian J Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fmed.2019.00209","article-title":"Interstitial pneumonia with autoimmune features (IPAF)","volume":"6","author":"Fernandes","year":"2019","journal-title":"Front Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.31138\/mjr.31.3.330","article-title":"Interstitial pneumonia with autoimmune features (IPAF): a single-Centre prospective study","volume":"31","author":"Karampeli","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmed.2020.609595","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"7","author":"Solomon","year":"2013","journal-title":"Front Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"152088","DOI":"10.1016\/j.semarthrit.2022.152088","article-title":"The role of myositis-specific autoantibodies and the Management of Interstitial Lung Disease in idiopathic inflammatory myopathies: a systematic review","volume":"57","author":"Teel","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked Immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000452225","article-title":"Integrated use of lung ultrasound and chest X-ray in the detection of interstitial lung disease","volume":"93","author":"Vizioli","year":"2017","journal-title":"Respiration"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation\u2013associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/s10165-011-0558-9","article-title":"Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140\/MDA5 autoantibodies","volume":"22","author":"Sato","year":"2012","journal-title":"Mod Rheumatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e00701","DOI":"10.1002\/rcr2.701","article-title":"Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease","volume":"9","author":"Kaenmuang","year":"2020","journal-title":"Respirol Case Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17843286.2017.1420521","article-title":"Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease \u2013 a case report","volume":"73","author":"De Backer","year":"2018","journal-title":"Acta Clin Belg"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12890-020-01256-x","article-title":"Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient","volume":"20","author":"Li","year":"2020","journal-title":"BMC Pulm Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J Intern Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"102666","DOI":"10.1016\/j.autrev.2020.102666","article-title":"What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?","volume":"19","author":"De Lorenzis","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10067-020-05292-0","article-title":"A Japanese-American female with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"40","author":"Takada","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical Spectrum in north American patients with Dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","article-title":"Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"61","author":"Gui","year":"2022","journal-title":"Rheumatol Oxf Engl."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive Dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2023","journal-title":"J Rheumatol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult Dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in Dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/17476348.2020.1767598","article-title":"Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series","volume":"14","author":"Bermudez","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1183\/16000617.00006714","article-title":"Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody","volume":"24","author":"Gossez","year":"2015","journal-title":"Eur Respir Rev"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","article-title":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis with interstitial lung disease","volume":"397","author":"Li","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.55563\/clinexprheumatol\/lqjx4h","article-title":"Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study","volume":"41","author":"Yan","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3899\/jrheum.211234","article-title":"Clinical heterogeneity of patients with antinuclear matrix protein 2 antibody\u2013positive myositis: a retrospective cohort study in China","volume":"49","author":"Li","year":"2022","journal-title":"J Rheumatol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with Cancer-associated Dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4103\/0019-5154.100486","article-title":"Clinical presentation and evaluation of Dermatomyositis","volume":"57","author":"Marvi","year":"2012","journal-title":"Indian J Dermatol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1007\/s10067-021-05797-2","article-title":"Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the argentine registry of inflammatory myopathies of the argentine Society of Rheumatology","volume":"40","author":"G\u00f3mez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s42358-019-0071-y","article-title":"Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis","volume":"59","author":"dos Passos Carvalho","year":"2019","journal-title":"Adv Rheumatol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","article-title":"Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol Int"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e20334","DOI":"10.7759\/cureus.20334","article-title":"A man with recurrent pneumonitis: a rare case of interstitial lung disease associated with anti-Mi-2 Beta-specific Dermatomyositis","volume":"13","author":"Ahmad","year":"2021","journal-title":"Cureus"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jdermsci.2005.09.004","article-title":"Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis","volume":"40","author":"Komura","year":"2005","journal-title":"J Dermatol Sci"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/jcm11071925","article-title":"Clinical characteristics of anti-TIF-1\u03b3 antibody-positive Dermatomyositis associated with malignancy","volume":"11","author":"Harada","year":"2022","journal-title":"J Clin Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"13030\/qt4fc9p1bd","DOI":"10.5070\/D3253043339","article-title":"A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor","volume":"25","author":"Varedi","year":"2019","journal-title":"Dermatol Online J"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/cancers13071528","article-title":"The association between TIF1 family members and Cancer Stemness in solid tumors","volume":"13","author":"Czerwinska","year":"2021","journal-title":"Cancers"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12890-021-01570-y","article-title":"Anti-TIF1 gamma-positive IPAF patient developed stage IVB lung squamous carcinoma in 1 year: a case report","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/1756-185X.13593","article-title":"Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: a potential unique subset of dermatomyositis-associated interstitial lung disease","volume":"22","author":"Gono","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/acr2.11247","article-title":"A north American cohort of anti-SAE Dermatomyositis: clinical phenotype, testing, and review of cases","volume":"3","author":"Albayda","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12969-021-00532-2","article-title":"Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report","volume":"19","author":"Kishi","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OARRR.S231195","article-title":"Myositis specific autoantibodies: a clinical perspective","volume":"12","author":"Alenzi","year":"2020","journal-title":"Open Access Rheumatol Res Rev"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s10067-019-04503-7","article-title":"The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e7962","DOI":"10.7759\/cureus.7962","article-title":"Anti-signal recognition particle antibody-associated severe interstitial lung disease requiring lung transplantation","volume":"12","author":"Qureshi","year":"2020","journal-title":"Cureus"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"101374","DOI":"10.1016\/j.rmcr.2021.101374","article-title":"Asymptomatic necrotizing myositis in a young male with progressive interstitial lung disease","volume":"32","author":"Baah","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"11032457","DOI":"10.1177\/1759720X211032457","article-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders","volume":"13","author":"Kuwana","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"778211","DOI":"10.3389\/fmed.2021.778211","article-title":"Interstitial lung disease is a major characteristic of patients who test positive for anti-PM\/Scl antibody","volume":"8","author":"Ge","year":"2022","journal-title":"Front Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12016-020-08814-5","article-title":"Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis","volume":"60","author":"Vojinovic","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","article-title":"The phenotype of myositis patients with anti-Ku autoantibodies","volume":"51","author":"Casal-Dominguez","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-022-05161-w","article-title":"The diagnostic challenge of patients with anti-U1-RNP antibodies","volume":"43","author":"Elhani","year":"2023","journal-title":"Rheumatol Int"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/RHU.0000000000001127","article-title":"Characterization of interstitial lung disease associated with anti-Ribonucleoprotein antibodies","volume":"26","author":"Lhote","year":"2020","journal-title":"JCR J Clin Rheumatol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.21037\/jtd-20-3328","article-title":"A narrative review of interstitial lung disease in anti-synthetase syndrome: a clinical approach","volume":"13","author":"Sawal","year":"2021","journal-title":"J Thorac Dis"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"e25816","DOI":"10.1097\/MD.0000000000025816","article-title":"Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies","volume":"100","author":"Jiang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/jcm9092944","article-title":"Prevalence of novel myositis autoantibodies in a large cohort of patients with interstitial lung disease","volume":"9","author":"Moll","year":"2020","journal-title":"J Clin Med"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/rheumatology\/keab488","article-title":"Myositis specific antibodies are associated with isolated anti-Ro-52 associated interstitial lung disease","volume":"61","author":"Shao","year":"2022","journal-title":"Rheumatology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1117071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:22:13Z","timestamp":1686644533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1117071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":102,"alternative-id":["10.3389\/fmed.2023.1117071"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1117071","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"1117071"}}